Peter van Mourik

156 Chapter 7 35. Joseph M. Collaco; Scott M. Blackman; Karen S. Raraigh; Harriet Corvol; Johanna M. Rommens; Rhonda G. Pace; Pierre-Yves Boelle; John McGready; Patrick R. Sosnay; Lisa J. Strug; Michael R. Knowles; Garry R. Cutting. Sources of Variation in Sweat Chloride Measurements in Cystic Fibrosis. Am J Respir Crit Care Med. 1–27 (2016) doi:10.1164/rccm.201002-0262OC. 36. Frank J. Accurso,, Steven M. Rowe, J.P. Clancy, Michael P. Boyle., Jordan M. Dunitz, Peter R. Durie, Scott D. Sagel, Douglas B. Hornick, M. W. K., Scott H. Donaldson, Richard B. Moss, Joseph M. Pilewski, Ronald C. Rubenstein, Ahmet Z. Uluer, Moira L. Aitken, Steven D. Freedman, L. M. R. & Nicole Mayer- Hamblett, Qunming Dong, Jiuhong Zha, Anne J. Stone, Eric R. Olson, Claudia L. Ordoñez, Preston W. Campbell, Melissa A. Ashlock, and B. W. R. Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTR Mutation. October 363 , 339–354 (2010). 37. Fidler, M. C., Beusmans, J., Panorchan, P. & Van Goor, F. Correlation of sweat chloride and percent predicted FEV1 in cystic fibrosis patients treated with ivacaftor. J. Cyst. Fibros. 1–4 (2016) doi:10.1016/j.jcf.2016.10.002. 38. Summary of Product Characteristics - Kalydeco. 1–76 (2018). 39. Summary of Product Characteristics - Orkambi . (2018). 40. Clevers, H. Modeling Development and Disease with Organoids. Cell 165 , 1586–1597 (2016). 41. Beekman, J. M. Individualized medicine using intestinal responses to CFTR potentiators and correctors. Pediatr. Pulmonol. 51 , S23–S34 (2016).